Zomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogs

ANN ARBOR, MI / ACCESSWIRE / March 7, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the publication of a case series article supporting the use of PulseVet electro-hydraulic shock wave therapy to successfully treat canine patients with fibrotic myopathy. This condition primarily affects breeds associated with Military and Police working dogs, such as German Shepherd Dogs. In this series, the patients were able to continue working an average of 32 months following diagnosis.

The article, titled "Outcome of eight working dogs with fibrotic myopathy following extracorporeal shockwave and rehabilitation therapy: a case series" was recently published in Frontiers in Veterinary Science. The study was conducted by Drs. Frank Tsai, Leilani Alvarez and the team at the Department of Integrative and Rehabilitative Medicine, Schwarzman Animal Medical Center (New York, NY), and is available here: https://www.frontiersin.org/articles/10.3389/fvets.2023.1258319/full

PulseVet's electrohydraulic shock wave therapy has been clinically validated for multiple indications in canine and equine patients such as tendon and ligament healing, bone healing, alleviation of chronic back pain, osteoarthritis, and wound healing.

Dr. Leilani Alvarez, Department Head of Integrative and Rehabilitative Medicine Department at the Schwarzman Animal Medical Center, and a co-author of the article, stated, "fibrotic myopathy is a career ending condition for these highly trained working dogs and has historically been virtually impossible to successfully treat. Having the ability to offer a treatment option to significantly extend their working life is extremely gratifying."

PulseVet's shock wave therapy harnesses high-energy sound waves to stimulate cells and promote the release of healing growth factors within the body which have been shown to modulate inflammation, enhance blood flow, increase bone density, and accelerate healing.

Adrian Lock, Vice President of Veterinary and Clinical Affairs at Zomedica, stated, "PulseVet shock wave continues to set the standard for clinically proven efficacy in animal healthcare. Considering the time and dedication put into training military and police dogs, this particular condition can be utterly devastating. Using PulseVet shock wave to treat these extremely valuable animals we may be able to keep them working several years longer than they might have following this diagnosis."